Early big-time college football matchups are all the rage, and the Philadelphia Eagles will have representatives in Austin for one of the most talent-rich games on the early college football schedule.
Philadelphia is among 16 NFL organizations expected to have scouts present when No. 1 Ohio State visits No. 4 Texas on Saturday night at Darrell K Royal-Texas Memorial Stadium. The game will begin at 7:30 p.m. ET on ABC. The Eagles will join the Cowboys, Seahawks, 49ers, Broncos, Colts, Patriots, Panthers, Lions, Chargers, Texans, Ravens, Rams, Dolphins, Jets and Browns in evaluating two rosters loaded with potential NFL talent.
Ohio State wide receiver Jeremiah Smith is expected to become one of the most coveted prospects in the 2027 draft. His matchup against Texas' secondary will give evaluators another opportunity to study his releases, route running, and ability to produce against top competition.
The following NFL teams will have reps present at Ohio State - Texas tonight:

• Eagles
• Cowboys
• Seahawks
• 49ers
• Broncos
• Colts
• Patriots
• Panthers
• Lions
• Chargers
• Texans
• Ravens
• Rams
• Dolphins
• Jets
• Browns
Buckeyes quarterback Julian Sayin and Texas quarterback Arch Manning will receive plenty of attention, even from organizations without an immediate need at the position. Comprehensive quarterback evaluations remain valuable because their eventual landing spots can influence the entire draft board. Texas edge defender Colin Simmons is another prospect capable of commanding the attention of Philadelphia's personnel department. His ability to pressure the quarterback and defend the run fits the athletic profile the Eagles have consistently valued along the defensive front.

#texas #state #philadelphia #colts

Former Duke Blue Devil Mark Williams and the Phoenix Suns have some bad news: Williams suffered a torn labrum in his left shoulder, was operated on Thursday, and is expected to be out for several months.
That's terrible news for Williams, but it could be very positive news for fellow Brotherhood member Khaman Maluach.
Expected to be Williams' understudy and to eventually become the starting center for the Suns, now there's a lot of pressure on Maluach to produce now.
He entered the NBA last year as a very raw rookie, but like we saw at Duke, he's a fast study. He got a lot out of his time in the G League, and we expect he'll continue his rapid improvement.
Obvious pivot could become Suns' calling card after Mark Williams' injury

#duke #mark #devil

Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 patients at up to 25 centers, with follow-up lasting up to five years.
For Nyxoah SA (NASDAQ:NYXH), the milestone begins a new phase of evidence collection following Genio's August 2025 FDA approval. The co-primary effectiveness endpoints are apnea-hypopnea-index and oxygen-desaturation-index responder rates at 12 months. Device- and procedure-related serious adverse events will be **** sed at 12 months and annually thereafter. The investment question is whether that evidence can help turn clinical credibility into sustained commercial adoption.
Nyxoah SA (NASDAQ:NYXH) has an opportunity to demonstrate how Genio performs across different physicians and treatment settings. Consistent outcomes across participating centers could give referring sleep physicians and implanting surgeons greater confidence in patient selection and treatment delivery.
The product offers a distinct approach. Genio stimulates hypoglossal nerves on both sides of the tongue, using a battery-free implant powered by an external wearable. For Nyxoah SA (NASDAQ:NYXH), documenting effectiveness and safety in routine practice could help physicians **** s how that design fits their patients' needs.
Longer follow-up could also strengthen the evidence available to payers. Nyxoah SA (NASDAQ:NYXH) could use sustained responses and safety findings to support coverage discussions, while participating centers gain practical experience with implantation and follow-up. That would make BREATHE valuable beyond a single headline response rate.

#nyxoah #NASDAQ #nyxh

Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
The Food and Drug Administration is now requiring Biohaven to ***** s the potential for human toxicity from a metabolite in the drug, opakalim. Opakalim is in testing as a treatment for focal onset seizures. But, in rats, it proved toxic.
Dosing is still ongoing. But the rodent toxicity setback likely delays potential regulatory approval. That's a boon for Xenon Pharmaceuticals (XENE), which is in late-stage testing with its drug, azetukalner. Both drugs work by opening potassium channels in the nervous system to calm overactive brain cells.
On the stock market today, Biohaven stock dropped 14.7% to 12.79. Shares fell below their 21-day and 50-day moving averages on the news, MarketSurge shows. Xenon stock slid a fraction to 58.80.
To ask for FDA approval, Biohaven will need the results of studies called RISE-2 and RISE-3. The hold was placed on the former, but the latter is still ongoing. The company expects to have the results from RISE-3 later this year.

#toxicity

A Brazilian federal judge ordered the immediate suspension of all environmental licenses held by Sigma Mineração S.A., the operating subsidiary of Sigma Lithium Corporation (NASDAQ:SGML), for the Grota do Cirilo project. The September 4 preliminary order also halted mining activities following a civil action brought by the Federation of Quilombola Communities of Minas Gerais.
The dispute centers on whether the project lies within the area of influence of the Baú Quilombola Community and therefore required free, prior, and informed consultation. The judge cited studies placing the community's territory approximately 2.7 kilometers from the project's directly affected area, within the 8-kilometer presumptive regulatory impact radius applicable to mining projects outside Brazil's Legal Amazon under Interministerial Ordinance No. 60/2015. Sigma Lithium Corporation (NASDAQ:SGML) has argued that the project is outside the relevant impact zone.
The court ordered independent georeferencing and barred Minas Gerais and its environmental agency from issuing new licenses, amendments, or corrective approvals until the community-protection requirements are completed.
Two routes remain. If independent georeferencing supports the boundary position, Sigma Lithium Corporation (NASDAQ:SGML) could seek favorable court relief modifying or reversing the suspension. This provides an alternative to completing the consultation requirements.
If the project falls within the regulated impact area, Sigma Lithium Corporation (NASDAQ:SGML) would need Incra approval of the Quilombola Component Study, Basic Quilombola Environmental Plan and Final Execution Report, plus free, prior and informed consultation with the Baú community. Completing those requirements could preserve the project if acceptable mitigation is agreed.

#corporation #sgml #project #community

Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease.
Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in the overall population. The endpoint combined cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization requiring hospitalization. Complete results have not yet been presented.
Royalty Pharma plc (NASDAQ:RPRX) provided Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with $500 million in January 2023. The transaction allocated $150 million to pelacarsen royalties and $350 million to Spinraza royalties. The clinical failure shifts the financial focus from uncertain pelacarsen upside to recovery through Spinraza.
Royalty Pharma plc (NASDAQ:RPRX) acquired 25% of the Spinraza royalties received by Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) through 2027. That share increases to 45% in 2028 on Spinraza annual sales of up to $1.5 billion.
Following the HORIZON result, the Spinraza interest will revert after aggregate payments to Royalty Pharma plc (NASDAQ:RPRX) reach $550 million, equal to 1.1 times the original funding. Management expects the structure to recover the entire investment and generate a modest positive return despite the clinical failure.

#royalty #pharma #cardiovascular #horizon

Falcons news: Which legendary RB did Bijan Robinson study to improve? appeared first on ClutchPoints. Add ClutchPoints as a Preferred Source by clicking here.
The Atlanta Falcons will be without projected starting quarterback Tua Tagovailoa for Sunday's Week 1 opener against the Pittsburgh Steelers, which could mean a bigger dose of star running back Bijan Robinson in offensive coordinator Tommy Rees' attack.
Robinson is hoping for a stellar season under new head coach Kevin Stefanski, who added an exciting new wrinkle to the Falcons' offense that Robinson believes plays to his strengths. Back-to-back 1,400-plus yard seasons have inspired confidence in Robinson, but the Falcons running back has bigger goals.
He spoke on Friday about the player he patterned his game after, name dropping one of the NFL's all-time greats on ESPN's This is Football show.
Watch sports LIVE with fuboTV (free trial)

#bijan

Annual U.S. cancer deaths tied to alcohol consumption more than doubled over a three-decade period, according to a recent study led by researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
The findings, published in The Lancet Regional Health — Americas and presented at the American Society of Clinical Oncology Annual Meeting in Chicago, revealed that alcohol-attributable cancer deaths jumped from 11,361 in 1990 to 23,126 in 2023.
Researchers ******* yzed more than 30 years of data from the Global Burden of Disease study to track the trends.
Beer, Wine Or Liquor? Massive Study Reveals Which Was Linked To Lower Death Risk
While alcohol has long been classified as a Group 1 carcinogen by the International Agency for Research on Cancer, surveys show that awareness of its link to cancer remains limited.

#study

LONDON, Sept 10 (Reuters) - The first visitors to the British Museum's blockbuster Bayeux Tapestry exhibition spoke of their excitement at seeing with their own eyes the 1,000-year-old embroidery many ‌remember from school lessons.
The sell-out display, which opened to the public on Thursday, has sparked ‌a Bayeux craze across Britain, with newspapers producing special guides, online discussions about securing tickets, and the pub opposite the museum temporarily changing its name to "The Beer Tapestry".
The masterpiece will be shown at the museum in central London for the next 10 months, having left France for the first time since the 11th century. It depicts the Norman invasion of England in 1066, the most famous date in the nation's history.
"It's just magical, isn't it?" ‌said Pauline Gairey, 53, a finance ⁠professional who had travelled from Wales, and recalled studying the tapestry at school.
'THE COLOUR IS STILL SO VIVID'

#bayeux #reuters #british

Options traders can spend hours searching for the right stock, studying charts, comparing fundamentals and trying to predict the market's next move.
But Barchart expert Rick Orford argues there's another question worth answering before any of that:
Options Flow Alert: Institutional Money Piles Into AMD Stock
Volatility Insurance for Applied Optoelectronics (AAOI) Stock Potentially Inspires a Contrarian Outlook
Unusual Options Activity Points to Big Institutional Bets on These 3 Industries

#options #institutional #money

Ella Beatty opened up about growing up in the "most loving" family, which happened to have three of Hollywood's biggest stars
Ella followed in the footsteps of her parents, Warren Beatty and Annette Bening, when she decided to become an actor
Fans in the comments remarked how similar Ella looks to Warren's older sister Shirley MacLaine
Ella Beatty is reflecting on her famous family — and some fans can't believe her resemblance to her famous aunt.
Ella, 26, opened up about her family in a Sept. 10 interview with Extra. She is the daughter of legendary actors Annette Bening and Warren Beatty. Warren, 89, followed in the footsteps of his older sister, Shirley MacLaine (who adapted her mother's maiden name for her stage name), when he got into acting. MacLaine, now 92, appeared on Broadway in the early 1950s as Warren was studying in New York City at the Stella Adler Studio of Acting.

#ella #annette

👋 Welcome to 5 Things PM! Princess Diana's head-turning "revenge dress" is going on sale for the first time in nearly 30 years.
Here's what else you might have missed during your busy day.
Sarah Pender/iStockphoto/Getty Images
Accidental ingestion of recreational drugs among young children in the US has surged by more than 3,300% over a 25-year period, according to a new study. An ER doctor explains what parents need to know.
Hunter Kozak was asking Charlie Kirk about mass shootings when Kirk was gunned down in front of him. Now, Kozak and other witnesses say they've faced relentless harassment and threats after online influencers falsely tied them to the killing.

#things #princess #images #accidental

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.

#phase #revenue #Growth

It looks like the American consumer has more to worry about than food recalls and cyclospora—a new study found that even the packaging the food comes in may pose some health concerns.
Out of over 15,000 food contact chemicals (FCCs), 1,222 or 8% can pose serious health risks, according to a recent study published in the peer-reviewed journal Environmental Science & Technology. Some of these FCCs, which in general are "substances that come into contact with food, such as through food packaging, processing, storage or other handling," per the FDA, were found to be hazardous to human health.
Researchers from the nonprofit Food Packaging Forum Foundation, which conducted the study, found at least 2,160 chemicals regularly contact food and "migrate into foodstuffs." Using guidelines from the UN's Globally Harmonized System of Classification and Labeling of Chemicals (GHS), researchers found some of the chemicals related to food packaging and other materials were "carcinogenic, mutagenic, toxic to reproduction, harmful to specific organs after repeated exposure, [and] endocrine disrupting."
That's not the only concerning part. The researchers found that 13,211 of the 15,159 known food-contact chemicals lacked harmonized hazard data. That means the scientists could not determine from the available data whether those chemicals met the study's criteria for being hazardous.
"There's a lot of ways of establishing whether something is hazardous or not, and some methods are based very much just on computer models, looking at the structure, predicting something. And others are based on in vitro tests," Dr. Helene Wiesinger, scientific communication officer at the nonprofit and one of the researchers on the study, told Fortune. "And in some sense, the data that we used?' So this is the data we used, and the problem we ran into at that point was that there were huge data lags."

#Food #study #contact

On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.

#phase

On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the pharmacy counter: ICOTYDE, an oral psoriasis treatment, and rusfertide, an injectable now awaiting an FDA decision. Cash and marketable securities climbed to $849.5 million. Here's what's fueling the optimism, and what could complicate it.
The quarter marked the first full three months of commercial sales for ICOTYDE, which won FDA approval on March 18 for moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg. That approval triggered a $50 million milestone payment and made ICOTYDE, according to the company, the first and only FDA-approved targeted oral peptide for the condition. Protagonist can still collect up to $580 million more in milestones from partner Johnson & Johnson, plus royalties that average around 7.25 percent at $4 billion in annual sales.
Rusfertide carries even more weight. Its new drug application sits under Priority Review with a PDUFA goal date in August, backed by Breakthrough Therapy, Orphan Drug, and Fast Track designations for polycythemia vera. Partner Takeda already paid Protagonist $200 million on an opt-out election in April, with another $200 million and a $75 million approval milestone still due, on top of royalties that can reach 29 percent of sales above $1.5 billion. Behind both drugs, PN-881, an oral IL-17 antagonist, is heading into a Phase 2b psoriasis program in early 2027 after Phase 1 data showed drug levels beating their pharmacokinetic targets, and a Phase 1 study just began for PN-477sc, an injectable obesity peptide.
Look closer at that $213.5 million in license and collaboration revenue, and $192.4 million of it traces to the proportional recognition of Takeda's initial opt-out payment, not repeatable product sales. A year earlier, the same line item was just $5.5 million, so the growth reflects a single deal event more than an operating business scaling up. And that opt-out itself cuts both ways: Protagonist gave up its right to develop and commercialize rusfertide on its own, trading full ownership for royalties and milestones that depend on Takeda's execution rather than Protagonist's.
Spending is also set to climb. Management expects research and development costs to increase significantly in the second half of 2026 versus the first half, driven by the new PN-881 Phase 2b program, manufacturing investments, and added headcount. General and administrative costs are rising too, largely on stock-based compensation. And rusfertide's fate still hinges on an FDA decision that hasn't happened yet, priority review or not.

#protagonist

Princess Leonor has officially become a university student after spending three years in the military.
The eldest daughter of King Felipe and Queen Letizia traded in her uniform for the classroom on Monday morning as she was spotted arriving at Carlos III University of Madrid to begin a four-year programme in Political Science.
At just before 9 am, she arrived alongside thousands of new students at the Getafe campus, just outside the capital.
The Princess, 20, looked effortlessly stunning in a casual white **** on-down T-shirt and denim jeans, with a black shoulder bag containing her studying essentials. She looked like a typical student with her blonde locks pulled back into a neat French braid.
The Princess, 20, looked just like any other university student (@ Getty Images)

#student #king #felipe #letizia

Patrick Surtain II spoke with reporters at the Broncos' facility this week about the version of Patrick Mahomes that Denver will meet at Arrowhead Stadium on Sept. 14, two days short of nine months after the Chiefs quarterback had surgery on his left knee.
Mahomes tore the ACL and LCL in that knee on Dec. 14 against the Chargers, taken down from behind on a scramble, and had surgery two days later in Dallas with Dr. Dan Cooper. He was initially told the recovery would run nine months. He has not missed a practice since being cleared for football work in July, and for the first time in his career he did not appear in a preseason game.
Feb 4, 2023; Paradise, NV, USA; AFC conterback Patrick Surtain II of the Denver Broncos (2) during Pro Bowl Games practice at Allegiant Stadium. Mandatory Credit: Kirby Lee-USA TODAY Sports
"It's really tough to tell 'cause coming off an injury like that, it's pretty tough, but I don't expect nothing less for him to be himself," Surtain said. "I mean, obviously they might change the scheme up for him a little bit, not allow him to run as much, but like you said, to be more of a pocket passer, which he's good at, so, it's still Patrick Mahomes at the end of the day, so, we still gotta prepare and study for him like the years past, so, we'll be ready."
Mahomes carried 64 times for 422 yards in 14 games last season, and the play that ended his year came on a scramble outside the pocket. Andy Reid has not said publicly how much of that usage he intends to keep, and Surtain named the likely adjustment before Kansas City described one.

#patrick #Broncos #denver

On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.

#opus #data

There's a new scholarship program for those interested in golf-course design and it's being started by one of the best in the game: Tom Doak.
According to a story in golfcoursearchitecture.net, the Doak Award will go out every two years to students who have showcased a commitment to a career in golf-course architecture.
"The purpose of the award is to further the education of promising young architects who have already demonstrated their dedication to a career in golf course design," Doak the publication. "It is really a write-your-own-award set-up, so that it's tailored to the gaps in each applicant's experience, whatever they think they are."
Doak has modeled this after the Dreer Award which he earned while at Cornell in the early 1980s. That award paid for him to travel and study golf courses. The Doak Award requires applicants to propose their own program of study and inlcude travel and educational pieces.
"I do expect travel to be an important part of the award, but I am keenly aware that it is much more expensive to see great courses today than when I spent nine months in the UK for about $10,000 in 1982," says Doak. "To that end, I am enlisting a bunch of my former clients to provide lodging and food in key locations, and asking fellow architects to host a student for a day or two if travelling to their part of the country."

#Career #study

(NewsNation) — Human urine left at Everest Base Camp is enough to melt more than 150 tons of ice and snow, according to a new study.
Researchers examined human activity on the Khumbu Glacier, where Everest Base Camp is located, during the 2023 spring climbing season.
Their findings, published in the journal Regional Environmental Change, suggest that activity at the camp generated enough heat to melt nearly 5,000 tons of snow and ice.
29% AI chatbot replies to voting questions inaccurate, outdated: Study
Of that total, scientists estimated that urine alone contributed to the melting of about 155 tons of ice and snow.

#everest

When people talk about shoplifting and organized retail crime (ORC), they tend to focus on the bottom-line impact on businesses. That makes sense because the numbers aren't small, according to the National Retail Federation's (NRF) The Impact of Theft & Violence 2026 report.
"The 2026 report demonstrates a concerning shift as criminals move beyond traditional shoplifting to more sophisticated external theft schemes, with retailers reporting higher rates of repeat offenders (50%), ORC-related incidents (40%), and walkout or pushout theft (37%). Fraud is also rising, with phone scams (69%), loyalty fraud (51%) and gift card theft or fraud (42%) increasing," the data showed.
The NRF, however, does not focus on how theft and thieves impact frontline retail workers.
A new report from HALOS, a bodycam company used by retailers like Walmart, Target, Kroger, TJ Maxx, H&M, and Aldi, shows that it does, and that the impact is quite severe.
"Two-thirds of frontline workers have experienced customer aggression acutely enough that they've considered leaving their job," according to HALOS' study of 2,500 frontline employees.

#according

Starting statin therapy shortly after a type 2 diabetes diagnosis may not only protect the heart — it may also be linked to a lower dementia risk.
A large study presented at the European Society of Cardiology Congress in Munich on Aug. 30 found that adults who began taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of developing dementia over 10 years compared to those who did not take the medication within five years.
Even for those who delayed starting a statin for one to five years, there was still a 10% lower relative risk, according to the findings, which were published in The Lancet Regional Health – Europe.
3 Things To Avoid In Middle Age Could Mean 13 More Years Without Dementia, Study Finds
A statin is a prescription medication that lowers "bad" LDL cholesterol and helps reduce the risk of heart attack and stroke.

#risk #lower #study #diagnosis

I'm a chef who is in the process of switching careers. I plan to pursue the Enrolled Agent credential. I'm also an avid investor. About four years ago, I started studying everything I could about investing and personal finance. I also encouraged my sister to do the same.
For most of my life, I had no idea that building wealth and having a positive net worth was something I could realistically achieve. I genuinely thought I was destined to depend almost entirely on Social Security in retirement. Now I know that poverty doesn't have to be my reality.
Bloom Energy was just named to the S&P 500. These other stocks are joining the index as well.
'It's not fair': My twin brother and I were left houses by our parents. Can I make him pay his share for taxes and upkeep?
Adobe just announced its next CEO. Here's why its stock is dropping.

#Social #bloom #process #switching

The keto diet may have surprising benefits for liver health, a new study suggests.
The research, published in the journal Cell Metabolism, studied 42 adults who had obesity, prediabetes and excess liver fat.
In a randomized clinical trial, the participants were ***** igned to three weight-loss diets – a low-carb ketogenic diet, a Mediterranean diet and a low-fat, mostly plant-based diet.
Secret To Weight Loss May Be Hiding In Your Gut, New Study Suggests
The keto diet's calories consisted of about 4% carbohydrates and 73% fat, according to the study. The Mediterranean diet provided about 50% of calories from carbohydrates and 35% from fat, while the low-fat diet provided about 70% of calories from carbohydrates and 15% from fat.

#liver

Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
When your income is limited, scaling back your budget can only get you so far. The good news: Cutting back on spending isn't the only way to improve your finances. You can potentially make big changes by finding a new source of income.
With the right side gig, putting in just a few extra hours of work per week could be enough to help you cover major bills and build up your savings. Follow these tips to ensure your venture is successful.
Finding the right side gig is a bit of an art. You'll need to figure out when you have free time, which skills people are willing to pay you for, and how much money you can realistically make once all of your personal expenses are covered. Here's what you should consider:
There are plenty of websites where you can list your services for hire, such as Lyft, Task Rabbit, and Fiverr, but they don't always pay well. According to a study from Human Rights Watch, people who used gig work platforms earned less than minimum wage after covering all of their work-related expenses.

#only #right

On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains on track for a new drug application submission for wet age-related macular degeneration in the fourth quarter of 2026, a plan the FDA effectively signed off on during a Type C meeting held in May. That timeline, paired with new data suggesting patients could need far fewer injections, is the headline. The rest of the report shows what it costs to get there.
AXPAXLI's case rests on the SOL-1 trial, which Ocular describes as the first successful superiority study of a new agent against an approved anti-VEGF therapy since that drug class arrived two decades ago. The FDA's May 2026 meeting minutes confirmed that SOL-1's efficacy and safety data, along with an interim safety look at the SOL-R trial and supporting evidence on axitinib, will be enough to support the NDA filing, and Ocular plans to file under the 505(b)(2) pathway, which could shave up to 60 days off a standard review.
A post hoc ***** ysis of SOL-1 adds a practical argument for the drug: applying SOL-R's stricter rescue criteria, Ocular estimates patients could need up to 72% fewer injections through 60 weeks, or 56% once the two loading doses are counted, than a patient on a typical every-eight-week aflibercept regimen, a gap that matters given that up to 40% of wet AMD patients quit treatment within their first year.
Early market research backs that pitch: about 80% of surveyed retina specialists said they would likely prescribe a drug with AXPAXLI's profile, and more than 90% expect to adopt it within a year of approval. The company says every Tier 1 payer it has engaged, across Medicare Advantage and commercial plans, has floated premium pricing for a more durable option. Underpinning all of it is a cash balance of $598.6 million as of June 30, which management expects to last into 2028.
Getting AXPAXLI to market is expensive, and the quarter showed it. Research and development spending rose to $54.1 million from $51.1 million a year earlier, selling and marketing costs climbed to $17.3 million from $13.7 million, and general and administrative expenses jumped to $22.2 million from $14.3 million, all tied to trial costs and a growing commercial team ahead of a launch that still is not approved. Net loss widened to $78.8 million from $67.8 million in the same quarter of 2025.

#quarter #costs

On August 13, Kodiak Sciences Inc. (NASDAQ:KOD) reported second-quarter financial results for the period ended June 30, alongside an update on its three late-stage eye disease programs. The clinical-stage biotech told investors it now sits within months of three separate Phase 3 readouts, a stretch CEO Victor Perlroth called the payoff of years of disciplined execution. For a company with no approved products and a widening cash burn, those trial results are about to decide a lot.
Kodiak's near-term story rests on Zenkuda and KSI-501, both being tested in the Phase 3 DAYBREAK study for treatment-naive wet age-related macular degeneration, with one-year primary endpoint topline data due in September 2026. Zenkuda already has four completed Phase 3 studies behind it. In GLOW1 and GLOW2, every patient remained on extended six-month dosing at one year, and in BEACON, nearly half of Zenkuda patients needed no further treatment in the second six months while matching aflibercept on vision and anatomical outcomes. That durability comes from a mean ocular half-life of 20 days, roughly three times longer than approved anti-VEGF drugs.
Behind DAYBREAK sits PEAK, evaluating KSI-101 in macular edema secondary to inflammation, where Kodiak finished enrolling the first 300-patient cohort during the quarter and expects Pivotal ***** ysis 1 data in December 2026. Earlier Phase 1b data showed more than half of MESI patients gaining at least 15 letters of vision, with over 90% resolution of retinal fluid by week eight. Kodiak also began enrolling patients in the roughly 910-patient ALTO study testing KSI-501 against aflibercept in diabetic macular edema, its second registrational trial for that molecule. Zenkuda and KSI-501 together are aimed at a $15 billion anti-VEGF market.
None of that comes cheap. Kodiak's net loss widened to $65.6 million in the second quarter of 2026, or $1.05 per share, up from $54.3 million and $1.03 per share a year earlier. R&D spending jumped to $56.1 million from $42.8 million, as the company ramped up clinical activity across PEAK and PINNACLE and stepped up manufacturing for its Phase 3 programs. General and administrative costs eased slightly to $10.8 million from $12.8 million, but that was not enough to offset the R&D increase.
Kodiak ended the quarter with $125.9 million in cash and equivalents, which management says covers operations into 2027, but working capital fell from $169.3 million at the end of 2025 to $78.6 million by June 30, and stockholders' equity dropped from $157.4 million to $61.1 million over the same stretch. With three separate trials due to report between September and December, any delay or disappointing result would hit a balance sheet that already has less room to absorb it.

#data

Justus Kelley of Virginia was crowned Miss USA on August 27, 2026. And while the pageant has garnered a slight controversial reputation, many of its contestants and winners went on to become internationally famous.
From Halle Berry to Olivia Culpo, some of our favorite stars' careers began on pageant stages. And every Miss USA contestant starts out competing for their own state. Over 50 years ago, Sharon Stone competed at Miss Pennsylvania and you won't recognize her in the rare photos from the event.
Crawford County is in Northwest PA
The Irreconcilable Differences actress was born in Meadville, Pennsylvania in 1958 and lived there until she was 15 years old. While studying creative writing at Edinboro State College, Sharon won the ******* le of Miss Crawford County, Pennsylvania.
The pageant is still put on today at the annual Crawford County Fair, with the judges looking for "a young lady that will represent our fair as an 'ambassador' of the PA fair, farm, livestock, and agricultural industry." The current holder is Stephanie Skinner.

#crawford #years

Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
• Can Fite Biopharma stock is at significant support. What is going on with CANF?
The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinoma (HCC).
The study focuses on HCC patients with Child-Pugh B7 cirrhosis, utilizing overall survival as its primary efficacy endpoint.
Because the observed data reflect a pooled, blinded population across both treatment arms, the company cannot draw conclusions regarding drug efficacy or comparative differences yet.

#biopharma #clinical